Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma - a systematic review and meta-analysis

Q: What patient population does this systematic review focus on?

Patients diagnosed with relapsed or refractory large B-cell lymphoma (R/R LBCL).

Q: Which CAR T-cell products are compared in the analysis?

The review compares lisocabtagene maraleucel (liso-cel), axicabtagene ciloleucel (axi-cel), and tisagenlecleucel (tisa-cel).

Q: What overall safety and efficacy signals are reported across the therapies?

Liso-cel shows promising efficacy with the lowest cytokine release syndrome rate, while neurologic events are lowest for tisa-cel; overall response and survival outcomes are compared at about 12 months post-treatment.

Sep 29, 2026

Uploaded by WPS_1786070896

This systematic review and meta-analysis evaluates efficacy and safety of CD19-targeted chimeric antigen receptor (CAR) T-cell therapies for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Studies were identified through searches of PubMed and Web of Science up to November 29, 2023, including cohort studies and single-arm clinical trials. Thirty-seven studies were pooled, comparing liso-cel, axi-cel, and tisa-cel across survival, response, and adverse events, showing liso-cel’s generally favorable balance while noting data limitations for real-world evidence.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages31

Reading Time1 h 18 min

AccessFree to download

Abstract

Background

Objective

Design

Data sources and methods

Results

Conclusion

Plain language summary

Keywords

Introduction

TherapeuTic advances in hematology Meta-analysis Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/ refractory large B-cell lymphoma: a systematic review and meta-analysis Qiang Li, Shenghua Xu, Yun Zhong, Peng Rao, Hui Huang andYan Huang Abstract Background: Individuals diagnosed with relapsed or refractory large B-cell lymphoma (R/RLBCL) typically exhibit a dismal prognosis when treated with conventional therapeutic modalities. CD19—targeted chimeric antigen receptor T (CAR-T) cell therapy has brought about a paradigm shift in the treatment paradigm of this disease. Nevertheless, a comprehensive assessment of the efficacy and safety profiles of diverse CAR-T products (e.g., axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel)) is imperative. Objective: This systematic review aims to systematically summarize and evaluate the efficacy and safety of CAR T-cell therapies for R/R LBCL through systematic review and meta-analytic approaches. Design: This is a systematic review and meta-analysis. Data sources and methods: Relevant studies were identified by systematically searching PubMed and Web of Science until November 29, 2023. Cohort studies and clinical trials were incorporated, with the inclusion of single-arm studies. CAR T-cell therapies are involved intisa-cel, axi-cel, and liso-cel. Proportions and their 95% confidence intervals were calculated using standard meta-analytic approaches. Results: Thirty-seven studies were included in meta-analyses, liso-cel demonstrated equivalent overall survival rates (70 .3%) to axi-cel (65 . 6%) at 12 months post-treatment, whereas tisa-cel was 48.0% . Objective response rate for liso-cel was comparable to axi-cel (79.0% vs 76.8%, pmeta-regression = 0.74), both of which were notably higher than those observed for tisa-cel (58.3%, both pmeta-regression < 0.05) . Regarding safety assessments, liso-cel exhibited the lowest cytokine release syndrome rate at 43. 0%, followed by tisa-cel at 70. 9%, and axi-celat 87. 9% . However, tisa-cel had the lowest incidence of neurologic events (14 . 9%), in contrast to liso-cel (21 . 1%) and axi-cel (52 .3%) . Conclusion: Based on the available evidence, liso-cel has shown promising efficacy and a manageable safety profile in patients with R/R LBCL, when compared to axi-cel and tisa-cel. However, real-world data on liso-cel are limited. Plain language summary A meta-analytic review for Chimeric antigen receptor T-cell therapy in relapsed/ refractory large B-cell lymphoma This study provides a comprehensive evaluation of three CAR T-cell therapies for treating aggressive lymphoma that has returned or stopped responding to treatment. The analysis shows that lisocabtagene maraleucel (liso-cel) performed similarly to axicabtagene TherAdv Hematol 2026, Vol. 17: 1–31 DOI: 10. 1177/ 20406207251407511 © The Author(s), 2026. Article reuse guidelines: [sagepub.com/journals](sagepub.com/journals)permissions Correspondence to: Yan Huang Hui Huang Department of Lymphatic and Hematologic Oncology, Jiangxi Cancer Hospital, 519 Beijing East Road, Nanchang, Jiangxi 330029, China [huangyan_333@163.com](huangyan_333@163.com)[ ](huangyan_333@163.com)[1364961938@qq.com](1364961938@qq.com) Qiang Li Shenghua Xu Yun Zhong Department of Lymphatic and Hematologic Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China Peng Rao Department of Lymphatic and Hematologic Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China [journals.sagepub.com/home/tah](journals.sagepub.com/home/tah) 1 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduc

FAQs

What patient population does this systematic review focus on?

Patients diagnosed with relapsed or refractory large B-cell lymphoma (R/R LBCL).

Which CAR T-cell products are compared in the analysis?

The review compares lisocabtagene maraleucel (liso-cel), axicabtagene ciloleucel (axi-cel), and tisagenlecleucel (tisa-cel).

What overall safety and efficacy signals are reported across the therapies?

Liso-cel shows promising efficacy with the lowest cytokine release syndrome rate, while neurologic events are lowest for tisa-cel; overall response and survival outcomes are compared at about 12 months post-treatment.

Sep 29, 2026

Uploaded by WPS_1786070896